Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Alzheimer's Research & Therapy
Published in: Alzheimer's Research & Therapy 5/2013

01-10-2013 | Review

Diets involved in PPAR and PI3K/AKT/PTEN pathway may contribute toneuroprotection in a traumatic brain injury

Authors: Yasuko Kitagishi, Satoru Matsuda

Published in: Alzheimer's Research & Therapy | Issue 5/2013

Login to get access

Abstract

Traumatic encephalopathy has emerged as a significant public health problem. Itis believed that traumatic encephalopathy is caused by exposure to repetitivebrain trauma prior to the initial symptoms of neurodegenerative disease.Therefore, prevention is important for the disease. The PI3K/AKT/PTEN(phosphoinositide-3 kinase/AKT/phosphatase and tensin homologue deleted onchromosome 10) pathway has been shown to play a pivotal role in neuroprotection,enhancing cell survival by stimulating cell proliferation and inhibitingapoptosis. PTEN negatively regulates the PI3K/AKT pathways through its lipidphosphatase activity. Although PTEN has been discovered as a tumor suppressor,PTEN is also involved in several other diseases, including diabetes andAlzheimer’s disease. Dietary fish oil rich in polyunsaturated fatty acidsmay induce the PTEN expression by activation of peroxisomeproliferator-activated receptor. Supplementation of these natural compounds mayprovide a new therapeutic approach to the brain disorder. We review recentstudies on the features of several diets and the signaling pathways involved intraumatic encephalopathy.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Cheng G, Kong RH, Zhang LM, Zhang JN: Mitochondria in traumatic brain injury and mitochondrial-targetedmultipotential therapeutic strategies. Br J Pharmacol. 2012, 16: 699-719.CrossRef
4.
Song SX, Gao JL, Wang KJ, Li R, Tian YX, Wei JQ, Cui JZ: Attenuation of brain edema and spatial learning deficits by the inhibition ofNADPH oxidase activity using apocynin following diffuse traumatic braininjury in rats. Mol Med Rep. 2012, Oct 24: [Epub ahead of print],
5.
Hellmich HL, Rojo DR, Micci MA, Sell SL, Boone DR, Crookshanks JM, DeWitt DS, Masel BE, Prough DS: Pathway analysis reveals common pro-survival mechanisms of metyrapone andcarbenoxolone after traumatic brain injury. PLoS One. 2013, 8: e53230-10.1371/journal.pone.0053230.PubMedCentralCrossRefPubMed
6.
Al-Gubory KH, Fowler PA, Garrel C: The roles of cellular reactive oxygen species, oxidative stress andantioxidants in pregnancy outcomes. Int J Biochem Cell Biol. 2010, 42: 1634-1650. 10.1016/j.biocel.2010.06.001.CrossRefPubMed
7.
Zhang Y, Du Y, Le W, Wang K, Kieffer N, Zhang J: Redox control of the survival of healthy and diseased cells. Antioxid Redox Signal. 2011, 15: 2867-2908. 10.1089/ars.2010.3685.CrossRefPubMed
8.
Scatena R: Mitochondria and cancer: a growing role in apoptosis, cancer cell metabolismand dedifferentiation. Adv Exp Med Biol. 2012, 942: 287-308. 10.1007/978-94-007-2869-1_13.CrossRefPubMed
9.
Ballard JW: Drosophila simulans as a novel model for studying mitochondrial metabolismand aging. Exp Gerontol. 2005, 40: 763-773. 10.1016/j.exger.2005.07.014.CrossRefPubMed
10.
Coleman CG, Wang G, Faraco G, Marques Lopes J, Waters EM, Milner TA, Iadecola C, Pickel VM: Membrane trafficking of NADPH oxidase p47(phox) in paraventricularhypothalamic neurons parallels local free radical production in angiotensinII slow-pressor hypertension. J Neurosci. 2013, 33: 4308-4316. 10.1523/JNEUROSCI.3061-12.2013.PubMedCentralCrossRefPubMed
11.
Li ZY, Yang Y, Ming M, Liu B: Mitochondrial ROS generation for regulation of autophagic pathways incancer. Biochem Biophys Res Commun. 2011, 414: 5-8. 10.1016/j.bbrc.2011.09.046.CrossRefPubMed
12.
Gillette-Guyonnet S, Secher M, Vellas B: Nutrition and neurodegeneration: epidemiological evidence and challenges forfuture research. Br J Clin Pharmacol. 2013, 75: 738-755.PubMedCentralCrossRefPubMed
13.
Choi BY, Jang BG, Kim JH, Lee BE, Sohn M, Song HK, Suh SW: Prevention of traumatic brain injury-induced neuronal death by inhibition ofNADPH oxidase activation. Brain Res. 2012, 1481: 49-58.CrossRefPubMed
14.
Asai T, Liu Y, Bae N, Nimer SD: The p53 tumor suppressor protein regulates hematopoietic stem cell fate. J Cell Physiol. 2011, 226: 2215-2221. 10.1002/jcp.22561.PubMedCentralCrossRefPubMed
15.
Xu J, Tian W, Ma X, Guo J, Shi Q, Jin Y, Xi J, Xu Z: The molecular mechanism underlying morphine-induced Akt activation: roles ofprotein phosphatases and reactive oxygen species. Cell Biochem Biophys. 2011, 61: 303-311. 10.1007/s12013-011-9213-5.CrossRefPubMed
16.
Howes AL, Arthur JF, Zhang T, Miyamoto S, Adams JW, Dorn GW, Woodcock EA, Brown JH: Akt-mediated cardiomyocyte survival pathways are compromised by G alphaq-induced phosphoinositide 4,5-bisphosphate depletion. J Biol Chem. 2003, 278: 40343-40351. 10.1074/jbc.M305964200.CrossRefPubMed
17.
Hou Q, Zhang D, Jarzylo L, Huganir RL, Man HY: Homeostatic regulation of AMPA receptor expression at single hippocampalsynapses. Proc Natl Acad Sci U S A. 2008, 105: 775-780. 10.1073/pnas.0706447105.PubMedCentralCrossRefPubMed
18.
Damjanac M, Rioux Bilan A, Paccalin M, Pontcharraud R, Fauconneau B, Hugon J, Page G: Dissociation of Akt/PKB and ribosomal S6 kinase signaling markers in atransgenic mouse model of Alzheimer’s disease. Neurobiol Dis. 2008, 29: 354-367. 10.1016/j.nbd.2007.09.008.CrossRefPubMed
19.
De Gasperi R, Sosa MA, Dracheva S, Elder GA: Presenilin-1 regulates induction of hypoxia inducible factor-1α: alteredactivation by a mutation associated with familial Alzheimer’sdisease. Mol Neurodegener. 2010, 5: 38-10.1186/1750-1326-5-38.PubMedCentralCrossRefPubMed
20.
Uemura K, Kuzuya A, Shimozono Y, Aoyagi N, Ando K, Shimohama S, Kinoshita A: GSK3beta activity modifies the localization and function of presenilin 1. J Biol Chem. 2007, 282: 15823-15832. 10.1074/jbc.M610708200.CrossRefPubMed
21.
Ryder J, Su Y, Ni B: Akt/GSK3beta serine/threonine kinases: evidence for a signalling pathwaymediated by familial Alzheimer’s disease mutations. Cell Signal. 2004, 16: 187-200. 10.1016/j.cellsig.2003.07.004.CrossRefPubMed
22.
Cheng B, Martinez AA, Morado J, Scofield V, Roberts JL, Maffi SK: Retinoic acid protects against proteasome inhibition associated cell death inSH-SY5Y cells via the AKT pathway. Neurochem Int. 2013, 62: 31-42. 10.1016/j.neuint.2012.10.014.CrossRefPubMed
23.
Haas-Kogan D, Stokoe D: PTEN in brain tumors. Expert Rev Neurother. 2008, 8: 599-610. 10.1586/14737175.8.4.599.CrossRefPubMed
24.
Gupta A, Dey CS: PTEN, a widely known negative regulator of insulin/PI3K signaling, positivelyregulates neuronal insulin resistance. Mol Biol Cell. 2012, 23: 3882-3898. 10.1091/mbc.E12-05-0337.PubMedCentralCrossRefPubMed
25.
Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR: Forkhead transcription factors are critical effectors of cell death and cellcycle arrest downstream of PTEN. Mol Cell Biol. 2000, 20: 8969-8982. 10.1128/MCB.20.23.8969-8982.2000.PubMedCentralCrossRefPubMed
26.
Mulholland DJ, Dedhar S, Wu H, Nelson CC: PTEN and GSK3beta: key regulators of progression to androgen-independentprostate cancer. Oncogene. 2006, 25: 329-337. 10.1038/sj.onc.1209020.CrossRefPubMed
27.
Fournier MV, Fata JE, Martin KJ, Yaswen P, Bissell MJ: Interaction of E-cadherin and PTEN regulates morphogenesis and growth arrestin human mammary epithelial cells. Cancer Res. 2009, 69: 4545-4552. 10.1158/0008-5472.CAN-08-1694.PubMedCentralCrossRefPubMed
28.
Zhang H, Liu R, Wang R, Hong S, Xu H, Zhang YW: Presenilins regulate the cellular level of the tumor suppressor PTEN. Neurobiol Aging. 2008, 29: 653-660. 10.1016/j.neurobiolaging.2006.11.020.PubMedCentralCrossRefPubMed
29.
Rochet JC, Hay BA, Guo M: Molecular insights into Parkinson’s disease. Prog Mol Biol Transl Sci. 2012, 107: 125-188.CrossRefPubMed
30.
Hajjar T, Meng GY, Rajion MA, Vidyadaran S, Othman F, Farjam AS, Li TA, Ebrahimi M: Omega 3 polyunsaturated fatty acid improves spatial learning and hippocampalperoxisome proliferator activated receptors (PPARα and PPARγ) geneexpression in rats. BMC Neurosci. 2012, 13: 109-10.1186/1471-2202-13-109.PubMedCentralCrossRefPubMed
31.
Yuan X, Zhang Z, Gong K, Zhao P, Qin J, Liu N: Inhibition of reactive oxygen species/extracellular signal-regulated kinasespathway by pioglitazone attenuates advanced glycation end products-inducedproliferation of vascular smooth muscle cells in rats. Biol Pharm Bull. 2011, 34: 618-623. 10.1248/bpb.34.618.CrossRefPubMed
32.
Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris TP, Rastinejad F: Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA. Nature. 2008, 456: 350-356.PubMedCentralCrossRefPubMed
33.
Tarrade A, Rochette-Egly C, Guibourdenche J, Evain-Brion D: The expression of nuclear retinoid receptors in human implantation. Placenta. 2000, 21: 703-710. 10.1053/plac.2000.0568.CrossRefPubMed
34.
Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O’Rahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W: International Union of Pharmacology. LXI. Peroxisome proliferator-activatedreceptors. Pharmacol Rev. 2006, 58: 726-741. 10.1124/pr.58.4.5.CrossRefPubMed
35.
Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT: PPARγ/RXRα-induced and CD36-mediated microglial amyloid-βphagocytosis results in cognitive improvement in amyloid precursorprotein/presenilin 1 mice. J Neurosci. 2012, 32: 17321-17331. 10.1523/JNEUROSCI.1569-12.2012.CrossRefPubMed
36.
Denner LA, Rodriguez-Rivera J, Haidacher SJ, Jahrling JB, Carmical JR, Hernandez CM, Zhao Y, Sadygov RG, Starkey JM, Spratt H, Luxon BA, Wood TG, Dineley KT: Cognitive enhancement with rosiglitazone links the hippocampal PPARγ andERK MAPK signaling pathways. J Neurosci. 2012, 32: 16725-16735a. 10.1523/JNEUROSCI.2153-12.2012.PubMedCentralCrossRefPubMed
37.
Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE: ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficitsin AD mouse models. Science. 2012, 335: 1503-1506. 10.1126/science.1217697.PubMedCentralCrossRefPubMed
38.
Stiles BL, Kuralwalla-Martinez C, Guo W, Gregorian C, Wang Y, Tian J, Magnuson MA, Wu H: Selective deletion of Pten in pancreatic beta cells leads to increased isletmass and resistance to STZ-induced diabetes. Mol Cell Biol. 2006, 26: 2772-2781. 10.1128/MCB.26.7.2772-2781.2006.PubMedCentralCrossRefPubMed
39.
Gorbenko O, Panayotou G, Zhyvoloup A, Volkova D, Gout I, Filonenko V: Identification of novel PTEN-binding partners: PTEN interaction with fattyacid binding protein FABP4. Mol Cell Biochem. 2010, 337: 299-305. 10.1007/s11010-009-0312-1.CrossRefPubMed
40.
Tsuda M, Inoue-Narita T, Suzuki A, Itami S, Blumenberg M, Manabe M: Induction of gene encoding FABP4 in Pten-null keratinocytes. FEBS Lett. 2009, 583: 1319-1322. 10.1016/j.febslet.2009.03.030.CrossRefPubMed
41.
Stiles B, Wang Y, Stahl A, Bassilian S, Lee WP, Kim YJ, Sherwin R, Devaskar S, Lesche R, Magnuson MA, Wu H: Liver-specific deletion of negative regulator Pten results in fatty liver andinsulin hypersensitivity [corrected]. Proc Natl Acad Sci U S A. 2004, 101: 2082-2087. 10.1073/pnas.0308617100.PubMedCentralCrossRefPubMed
42.
Lecka-Czernik B: Aleglitazar, a dual PPARα and PPARγ agonist for the potential oraltreatment of type 2 diabetes mellitus. IDrugs. 2010, 13: 793-801.PubMed
43.
Knobbe CB, Lapin V, Suzuki A, Mak TW: The roles of PTEN in development, physiology and tumorigenesis in mousemodels: a tissue-by-tissue survey. Oncogene. 2008, 27: 5398-5415. 10.1038/onc.2008.238.CrossRefPubMed
44.
Yoshida H, Okumura N, Kitagishi Y, Nishimura Y, Matsuda S: Ethanol extract of rosemary repressed PTEN expression in K562 culturecells. Int J Appl Biol Pharm Technol. 2011, 2: 316-322.
45.
Delgado-Esteban M, Martin-Zanca D, Andres-Martin L, Almeida A, Bolaños JP: Inhibition of PTEN by peroxynitrite activates thephosphoinositide-3-kinase/Akt neuroprotective signaling pathway. J Neurochem. 2007, 102: 194-205. 10.1111/j.1471-4159.2007.04450.x.CrossRefPubMed
46.
Fuentealba RA, Liu Q, Kanekiyo T, Zhang J, Bu G: Low density lipoprotein receptor-related protein 1 promotes anti-apoptoticsignaling in neurons by activating Akt survival pathway. J Biol Chem. 2009, 284: 34045-34053. 10.1074/jbc.M109.021030.PubMedCentralCrossRefPubMed
47.
Chen LM, Xiong YS, Kong FL, Qu M, Wang Q, Chen XQ, Wang JZ, Zhu LQ: Neuroglobin attenuates Alzheimer-like tau hyperphosphorylation by activatingAkt signaling. J Neurochem. 2012, 120: 157-164. 10.1111/j.1471-4159.2011.07275.x.CrossRefPubMed
48.
Zhang C, Browne A, Child D, Tanzi RE: Curcumin decreases amyloid-beta peptide levels by attenuating the maturationof amyloid-beta precursor protein. J Biol Chem. 2010, 285: 28472-28480. 10.1074/jbc.M110.133520.PubMedCentralCrossRefPubMed
49.
Sharma S, Ying Z, Gomez-Pinilla F: A pyrazole curcumin derivative restores membrane homeostasis disrupted afterbrain trauma. Exp Neurol. 2010, 226: 191-199. 10.1016/j.expneurol.2010.08.027.PubMedCentralCrossRefPubMed
50.
Laird MD, Sukumari-Ramesh S, Swift AE, Meiler SE, Vender JR, Dhandapani KM: Curcumin attenuates cerebral edema following traumatic brain injury in mice:a possible role for aquaporin-4?. J Neurochem. 2010, 113: 637-648. 10.1111/j.1471-4159.2010.06630.x.PubMedCentralCrossRefPubMed
51.
Wu Q, Chen Y, Li X: HDAC1 expression and effect of curcumin on proliferation of Raji cells. J Huazhong Univ Sci Technolog Med Sci. 2006, 26: 199-201. 10.1007/BF02895815.CrossRefPubMed
52.
Wang R, Li YH, Xu Y, Li YB, Wu HL, Guo H, Zhang JZ, Zhang JJ, Pan XY, Li XJ: Curcumin produces neuroprotective effects via activating brain-derivedneurotrophic factor/TrkB-dependent MAPK and PI-3K cascades in rodentcortical neurons. Prog Neuropsychopharmacol Biol Psychiatry. 2010, 34: 147-153. 10.1016/j.pnpbp.2009.10.016.CrossRefPubMed
53.
Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, Chen PP, Hudspeth B, Chen C, Zhao Y, Vinters HV, Frautschy SA, Cole GM: Beta-amyloid oligomers induce phosphorylation of tau and inactivation ofinsulin receptor substrate via c-Jun N-terminal kinase signaling:suppression by omega-3 fatty acids and curcumin. J Neurosci. 2009, 29: 9078-9089. 10.1523/JNEUROSCI.1071-09.2009.PubMedCentralCrossRefPubMed
54.
Yoshida H, Okumura N, Nishimura Y, Kitagishi Y, Matsuda S: Turmeric and curcumin suppress presenilin 1 protein expression in Jurkatcells. Exp Ther Med. 2011, 2: 629-632.PubMedCentralPubMed
55.
Kadish I, van Groen T: Lesion-induced hippocampal plasticity in transgenic Alzheimer’s diseasemouse models: influences of age, genotype, and estrogen. J Alzheimers Dis. 2009, 18: 429-445.PubMed
56.
Liang C, Li H, Shen C, Lai J, Shi Z, Liu B, Tao HM: Genistein potentiates the anti-cancer effects of gemcitabine in humanosteosarcoma via the downregulation of Akt and nuclear factor-κBpathway. Anticancer Agents Med Chem. 2012, 12: 554-563. 10.2174/187152012800617867.CrossRefPubMed
57.
Villaflores OB, Chen YJ, Chen CP, Yeh JM, Wu TY: Curcuminoids and resveratrol as anti-Alzheimer agents. Taiwan J Obstet Gynecol. 2012, 51: 515-525. 10.1016/j.tjog.2012.09.005.CrossRefPubMed
58.
Huang TC, Lu KT, Wo YY, Wu YJ, Yang YL: Resveratrol protects rats from Aβ-induced neurotoxicity by the reductionof iNOS expression and lipid peroxidation. PLoS One. 2011, 6: e29102-10.1371/journal.pone.0029102.PubMedCentralCrossRefPubMed
59.
Li F, Gong Q, Dong H, Shi J: Resveratrol, a neuroprotective supplement for Alzheimer’s disease. Curr Pharm Des. 2012, 18: 27-33. 10.2174/138161212798919075.CrossRefPubMed
60.
Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE: Dietary supplementation with resveratrol reduces plaque pathology in atransgenic model of Alzheimer’s disease. Neurochem Int. 2009, 54: 111-118. 10.1016/j.neuint.2008.10.008.PubMedCentralCrossRefPubMed
61.
Capiralla H, Vingtdeux V, Zhao H, Sankowski R, Al-Abed Y, Davies P, Marambaud P: Resveratrol mitigates lipopolysaccharide- and Aβ-mediated microglialinflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade. J Neurochem. 2012, 120: 461-472. 10.1111/j.1471-4159.2011.07594.x.PubMedCentralCrossRefPubMed
62.
Kouroumichakis I, Papanas N, Zarogoulidis P, Liakopoulos V, Maltezos E, Mikhailidis DP: Fibrates: therapeutic potential for diabetic nephropathy?. Eur J Intern Med. 2012, 23: 309-316. 10.1016/j.ejim.2011.12.007.CrossRefPubMed
63.
Friedland SN, Leong A, Filion KB, Genest J, Lega IC, Mottillo S, Poirier P, Reoch J, Eisenberg MJ: The cardiovascular effects of peroxisome proliferator-activated receptoragonists. Am J Med. 2012, 125: 126-133. 10.1016/j.amjmed.2011.08.025.CrossRefPubMed
64.
Fu J, Zhang XW, Liu K, Li QS, Zhang LR, Yang XH, Zhang ZM, Li CZ, Luo Y, He ZX, Zhu HL: Hypolipidemic activity in Sprague–Dawley rats and constituents of anovel natural vegetable oil from Cornus wilsoniana fruits. Food Sci. 2012, 77: H160-H169. 10.1111/j.1750-3841.2012.02786.x.CrossRef
65.
Donohue MC, Aisen PS: Mixed model of repeated measures versus slope models in Alzheimer’sdisease clinical trials. J Nutr Health Aging. 2012, 16: 360-364. 10.1007/s12603-012-0047-7.CrossRefPubMed
66.
Shah R: The role of nutrition and diet in Alzheimer disease: a systematic review. J Am Med Dir Assoc. 2013, 14: 398-402. 10.1016/j.jamda.2013.01.014.CrossRefPubMed
67.
68.
Calon F: Omega-3 polyunsaturated fatty acids in Alzheimer’s disease: keyquestions and partial answers. Curr Alzheimer Res. 2011, 8: 470-478. 10.2174/156720511796391881.CrossRefPubMed
69.
Goncalves MB, Clarke E, Hobbs C, Malmqvist T, Deacon R, Jack J, Corcoran JP: Amyloid β inhibits retinoic acid synthesis exacerbating Alzheimerdisease pathology which can be attenuated by an retinoic acid receptorα agonist. Eur J Neurosci. 2013, 37: 1182-1192. 10.1111/ejn.12142.PubMedCentralCrossRefPubMed
70.
Lerner AJ, Gustaw-Rothenberg K, Smyth S, Casadesus G: Retinoids for treatment of Alzheimer’s disease. Biofactors. 2012, 38: 84-89. 10.1002/biof.196.CrossRefPubMed
Metadata
Title
Diets involved in PPAR and PI3K/AKT/PTEN pathway may contribute toneuroprotection in a traumatic brain injury
Authors
Yasuko Kitagishi
Satoru Matsuda
Publication date
01-10-2013
Publisher
BioMed Central
Published in
Alzheimer's Research & Therapy / Issue 5/2013
Electronic ISSN: 1758-9193
DOI
https://doi.org/10.1186/alzrt208

Other articles of this Issue 5/2013

Alzheimer's Research & Therapy 5/2013 Go to the issue

Research

Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease

Review

The role of APP and BACE1 trafficking in APP processing and amyloid-β generation

Review

Dominantly Inherited Alzheimer Network: facilitating research and clinical trials

Research

Progression of mild Alzheimer’s disease: knowledge and prediction models required for future treatment strategies

Research

Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples

Review

Apolipoprotein E as a β-amyloid-independent factor in Alzheimer’s disease